BIOMAT Database Logo BIOMAT Database Logo

[Intermittent treatment of "intractable chronic tuberculosis" by combined rifampicin-ethambutol: preliminary results of a controlled survey made in Algeria]. 1970

D Larbaoui, and P Chaulet, and J Grosset, and K Abderrahim, and N Oussedik, and C Coucke, and L Benabdallah

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D004977 Ethambutol An antitubercular agent that inhibits the transfer of mycolic acids into the cell wall of the tubercle bacillus. It may also inhibit the synthesis of spermidine in mycobacteria. The action is usually bactericidal, and the drug can penetrate human cell membranes to exert its lethal effect. (From Smith and Reynard, Textbook of Pharmacology, 1992, p863) Dexambutol,EMB-Fatol,EMB-Hefa,Etambutol Llorente,Ethambutol Hydrochloride,Etibi,Miambutol,Myambutol,EMB Fatol,EMB Hefa,Hydrochloride, Ethambutol,Llorente, Etambutol
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000462 Algeria A country in northern Africa bordering the Mediterranean Sea, between MOROCCO and TUNISIA. Its capital is Algiers.

Related Publications

D Larbaoui, and P Chaulet, and J Grosset, and K Abderrahim, and N Oussedik, and C Coucke, and L Benabdallah
Combined treatment with rifampicin-ethambutol-capreomycin in chronic open pulmonary tuberculosis.
January 1969, Acta tuberculosea et pneumologica Belgica,
D Larbaoui, and P Chaulet, and J Grosset, and K Abderrahim, and N Oussedik, and C Coucke, and L Benabdallah
[Immediate results of strictly supervised, intermittent treatment with rifampicin and ethambutol in patients with chronic pulmonary tuberculosis].
January 1977, Revista de igiena, bacteriologie, virusologie, parazitologie, epidemiologie, pneumoftiziologie. Pneumoftiziologia,
D Larbaoui, and P Chaulet, and J Grosset, and K Abderrahim, and N Oussedik, and C Coucke, and L Benabdallah
Side effects during intermittent rifampicin and ethambutol treatment. A preliminary report.
January 1973, Scandinavian journal of respiratory diseases. Supplementum,
D Larbaoui, and P Chaulet, and J Grosset, and K Abderrahim, and N Oussedik, and C Coucke, and L Benabdallah
[Results of intermittent biweekly treatment with rifampicin and ethambutol in silicotuberculosis].
January 1979, Revista de igiena, bacteriologie, virusologie, parazitologie, epidemiologie, pneumoftiziologie. Pneumoftiziologia,
D Larbaoui, and P Chaulet, and J Grosset, and K Abderrahim, and N Oussedik, and C Coucke, and L Benabdallah
[Intermittent ambulatory treatment with rifampicin and ethambutol in a program of neutralization of chronic sources of elimination of resistant germs. (Preliminary results)].
January 1973, Ftiziologia,
D Larbaoui, and P Chaulet, and J Grosset, and K Abderrahim, and N Oussedik, and C Coucke, and L Benabdallah
[Rifampicin and ethambutol in the treatment of chronic destructive tuberculosis].
January 1971, Problemy tuberkuleza,
D Larbaoui, and P Chaulet, and J Grosset, and K Abderrahim, and N Oussedik, and C Coucke, and L Benabdallah
[Treatment of chronic tuberculosis patients with ethambutol and protoionamide combined with rifampicin and capreomicin].
January 1968, Giornale italiano di chemioterapia,
D Larbaoui, and P Chaulet, and J Grosset, and K Abderrahim, and N Oussedik, and C Coucke, and L Benabdallah
[Intermittent chemotherapy of pulmonary tuberculosis with rifampicin and ethambutol].
October 1978, Problemy tuberkuleza,
D Larbaoui, and P Chaulet, and J Grosset, and K Abderrahim, and N Oussedik, and C Coucke, and L Benabdallah
[Rifampicin and ethambutol treatment experience in chronic destructive pulmonary tuberculosis].
March 1981, Problemy tuberkuleza,
D Larbaoui, and P Chaulet, and J Grosset, and K Abderrahim, and N Oussedik, and C Coucke, and L Benabdallah
[Treatment of chronic destructive pulmonary tuberculosis with rifampicin and ethambutol].
January 1971, Problemy tuberkuleza,
Copied contents to your clipboard!